BlackRock Advisors’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

BlackRock Advisors’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-13,479	Closed	-$282K	–	3805
2016 Q3	$282K	Buy	13,479 +3,401	+34%	+$39.2K	﹤0.01%	2489
2016 Q2	$109K	Buy	10,078 +4,280	+74%	+$36.6K	﹤0.01%	2929
2016 Q1	$38K	Hold	5,798	–	–	﹤0.01%	3250
2015 Q4	$105K	Sell	5,798 -1,904	-25%	-$26.2K	﹤0.01%	2903
2015 Q3	$85K	Sell	7,702 -82,829	-91%	-$880K	﹤0.01%	3159
2015 Q2	$1.3M	Sell	90,531 -7,546	-8%	-$102K	﹤0.01%	1485
2015 Q1	$1.15M	Buy	+98,077	New	+$1.32M	﹤0.01%	1481

BlackRock Advisors's VTAE Position: Q4 2016 in Review

BlackRock Advisors sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 13,479 shares — an estimated $282K sold.

BlackRock Advisors first reported a position in VTAE in Q1 2015 and held it in 7 quarters. The position peaked at $1.3M in Q2 2015. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

BlackRock Advisors reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
BlackRock Advisors sold 13,479 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $282K.
BlackRock Advisors first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2015 and held it in 7 quarters.
BlackRock Advisors's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $1.3M in Q2 2015.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.